BETA Technologies launches IPO of 25 million shares priced $27-$33
NEW YORK/FRANKLIN LAKES - BD (NYSE:BDX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $55.2 billion, and Opentrons Labworks announced Wednesday a multi-year collaboration to integrate robotic liquid-handling capabilities into BD’s single-cell multiomics instruments, aiming to streamline disease research and drug development processes.
The partnership will combine BD’s Rhapsody System with Opentrons’ Flex platform to enable hands-free workflows for single-cell multiomics experiments. A key component of the collaboration includes developing an automation-compatible module for the BD Rhapsody System that will automate next-generation sequencing library preparation and cell capture steps.
"By integrating robotics with our instruments — including the BD Rhapsody HT Xpress System which enables million-cell studies — we are helping scientists access potentially life-changing insights with greater speed, scale and reproducibility," said Ranga Partha, VP/GM of Global Marketing and Strategic Growth Areas at BD Biosciences, in a press release statement. The company’s strong market position is reflected in its annual revenue of $21.4 billion and robust financial health score rated as "GOOD" by InvestingPro.
James Atwood, CEO of Opentrons Labworks, noted that the collaboration aims to make cutting-edge single-cell sequencing more accessible and cost-effective for laboratories across basic and translational research.
The companies will offer early access opportunities for interested laboratories soon. More information will be available at the American Society of Human Genetics Annual Meeting in Boston, scheduled for October 14-18, 2025, where both companies will have exhibition booths.
BD is a global medical technology company with more than 70,000 employees worldwide, while Opentrons is a life science company focused on lab automation that has raised over $200 million in funding and achieved unicorn status. According to InvestingPro analysis, BD’s stock currently trades below its Fair Value, presenting a potential opportunity for investors. For deeper insights into BD’s valuation and 12+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Becton Dickinson reported impressive third-quarter earnings for 2025, with revenue reaching $5.5 billion, slightly exceeding the anticipated $5.49 billion. The company’s earnings per share came in at $3.68, surpassing the consensus estimate of $3.40, marking an 8.24% surprise. Piper Sandler responded by raising its price target for Becton Dickinson stock to $200, up from $185, while maintaining a Neutral rating. Additionally, the company is planning a significant corporate restructuring, with the intention to spin off and merge its Biosciences and Diagnostics businesses with Waters in the first quarter of 2026. RBC Capital initiated coverage on Becton Dickinson with a Sector Perform rating and set a price target of $211. In another development, Becton Dickinson announced a partnership with Henry Ford Health to automate pharmacy services using the BD Rowa Vmax system. This technology will be implemented in hospital-based community pharmacies in Southeast and Central Michigan, allowing for 24/7 prescription pickups. These recent developments reflect Becton Dickinson’s strategic efforts to enhance its operations and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.